October 31st 2024
Motivators like health benefits, altruism, and trust in clinicians enhance participant retention and adherence in melanoma research, according to MEL-SELF findings.
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Dermalorian™ Webinar Series on Moderate to Severe Atopic Dermatitis
November 21, 2024 - December 5, 2024
View More
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Combos Lead Excitement in BRAF+ Melanoma, but More Pain Points are Ready to be Tackled
March 30th 2021Michael A. Davies, MD, PhD, discusses how he currently approaches treatment for patients advanced BRAF-mutant melanoma as well as exciting areas of current research to address ongoing questions in the community.
Utility of PRAME staining in identifying malignant transformation of melanocytic nevi
December 9th 2020Recently, PRAME (preferentially expressed antigen in melanoma) immunohistochemical staining has shown its usefulness in distinguishing benign from malignant melanocytic cell populations, offering another color to the canvas in the quest for a more definitive diagnosis of melanoma.
Mohs micrographic presents challenges in kids
November 25th 2020While Mohs micrographic surgery is well established as a safe and effective therapeutic modality in adult patients, it is not as commonly used in pediatric populations. There are unique challenges to performing Mohs surgery on pediatric patients, especially with patient cooperation. Multidisciplinary planning may be needed.
Future of immunotherapy in melanoma to focus on overcoming resistance, personalizing regimens
November 19th 2020With an estimated 5-year survival rate of 50% and an ongoing issue of resistance, next steps with immunotherapy in melanoma will focus on stratifying patients, personalizing therapy, and refining localized regimens.
Women surgeons and Mohs micrographic surgery in the U.S.
October 21st 2020Michelle Nguyen, M.D., MPH, sits down with Dermatology Times to discuss her recent presentation at the 2020 American Society for Dermatologic Surgery (ASDS) virtual meeting regarding the representation of women dermatologic surgeons in the U.S.
Emerging options for high-risk melanoma
August 26th 2020Recruiting is ongoing for an investigator-initiated clinical trial of pembrolizumab in clinical stage 2B/C melanoma which will investigate the effects of treatment with pembrolizumab before surgery to remove melanoma on the rate of positive sentinel lymph nodes in patients with stage IIB/C melanoma.
Collaboration makes progresses standards for implementing AI
August 11th 2020The International Skin Imaging Collaboration is an academic and industry partnership designed to facilitate the clinical application of digital skin imaging, with an initial focus on melanoma. The group is developing standards for dermatologic imaging and building a public archive of clinical and dermoscopic images for use in developing artificial intelligence diagnostic algorithms.
FDA approves combination treatment for advanced melanoma
July 30th 2020The U.S. Food and Drug Administration has approved atezolizumab plus cobimetinib and vemurafenib for treatment of BRAF V600 mutation-positive advanced melanoma. Studies show the combination treatment prolonged patients’ lives by 15 months without disease worsening.